米アロイ・セラピューティクス、 湘南ヘルスイノベーションパークに新拠点を設立
– 米バイオテクノロジー企業、アロイ・セラピューティクスが日本初の子会社を設立
– 主要モダリティである細胞治療の研究拠点を初めて日本に開設し、独自のiCAR-T技術を本格的に展開
Alloy Therapeutics enters Japanese market by establishing operations at Shonan Health Innovation Park
US-based biotech ecosystems company establishes subsidiary in key Japanese market with launch of its first cell therapy base in Japan, a key modality for Alloy to fully advance its proprietary iCAR-T technology.
Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform
Collaboration builds on Alloy’s existing and highly productive engagement with Pfizer and will apply Alloy’s innovation expertise to address Pfizer’s specific antibody discovery objectives
Ypsilon Receives $2.7 Million Non-Dilutive Grant to Advance Next-Generation TCRm Antibodies
Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) provides external validation of Ypsilon’s platform and lead asset
Alloy Therapeutics Announces New Licensing Model for ATX-Gx™ Antibody Discovery Platform and Launches mAbForge™ High-Throughput Screening Service
Boston, MA, January 9th, 2025 – Alloy Therapeutics (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today that it is launching a new market-disrupting licensing structure. Partners can now have the option to use the ATX-GxTM antibody technology platform with no annual access fee or development milestones. […]
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi
Boston, MA, January 7th, 2025 – Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target specific collaboration and license agreement for the use of their novel and proprietary AntiClastic Antisense Platform with Sanofi for a central nervous system (CNS) target. In return, […]
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
Tokyo & Boston, November 20, 2024 – Alloy Therapeutics Inc. ( “Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) […]
Alloy Therapeutics Announces Institutional License Agreement with Scripps Research for its ATX-Gx™ Platform for Fully Human Antibody Discovery
— Agreement provides Scripps Research scientists with broad access to Alloy’s fully human transgenic mouse platform, which has the power to increase the pace and success rate of antibody discovery and vaccine development efforts. — BOSTON, Mass., October 30th, 2024 – Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms […]
Alloy Therapeutics Announces Platform License Agreement with Lilly
BOSTON, Mass., May 21st, 2024 – Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms and services, announced today a licensing agreement for its murine platforms for fully human antibody discovery with Eli Lilly and Company. The non-exclusive license provides Lilly access to the ATX-Gx™ and ATX-CLC™ mouse platforms […]
Cantai Therapeutics is Co-Founded by Agent Capital and 82VS to Advance Next-Generation Bispecific Antibodies for Autoimmune Diseases
WALTHAM, Mass., November 20th, 2023 – Cantai Therapeutics (“Cantai”) today announced its formation and the completion of a seed financing co-led by Agent Capital and 82VS (the affiliated venture studio of Alloy Therapeutics) with additional participation from Tellus BioVentures. The proceeds will be used to develop drug candidates to treat autoimmune and inflammatory disorders by […]
